ArticleAmerican journal of cardiovascular disease2011
Inflammasomes in cardiovascular diseases.
Article in American journal of cardiovascular disease, 2011. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 34 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
34 citing papers in PubMed, 45 citations in OpenAlex.
- Unleashing the potential of exercise: conquering cardiovascular disease by targeting inflammasome activation.European journal of medical research · 2025Review
- Inflammasomes in Cardiovascular Diseases: Current Knowledge and Future Perspectives.International journal of molecular sciences · 2025Review
- NLRP3 inflammasome: a key player in the pathogenesis of life-style disorders.Experimental & molecular medicine · 2024Review
- miR-135 protects against atrial fibrillation by suppressing intracellular calcium-mediated NLRP3 inflammasome activation.Journal of cell communication and signaling · 2023Article
- The therapeutic potential of sphingolipids for cardiovascular diseases.Frontiers in cardiovascular medicine · 2023Review
- Lung Inflammasome Activation in SARS-CoV-2 Post-Mortem Biopsies.International journal of molecular sciences · 2022Article
- Cardioprotective Antioxidant and Anti-Inflammatory Mechanisms Induced by Intermittent Hypobaric Hypoxia.Antioxidants (Basel, Switzerland) · 2022Article
- The Evolving Role of Nucleotide-binding Oligomerisation Domain-like Receptor Pyrin Domain 3 Inflammasome Activation in Vascular Endothelial Cells: A Review.The Malaysian journal of medical sciences : MJMS · 2022Review
- Emerging Roles of Inflammasomes in Cardiovascular Diseases.Frontiers in immunology · 2022Review
- Involvement of ectonucleotidases and purinergic receptor expression during acute Chagas disease in the cortex of mice treated with resveratrol and benznidazole.Purinergic signalling · 2021Article
- The Role of Melatonin on NLRP3 Inflammasome Activation in Diseases.Antioxidants (Basel, Switzerland) · 2021Review
- Article
- Rejection-associated Mitochondrial Impairment After Heart Transplantation.Transplantation direct · 2020Article
- Targeted anti-IL-1β platelet microparticles for cardiac detoxing and repair.Science advances · 2020Article
- Insights Into the Role of Mitochondrial Ion Channels in Inflammatory Response.Frontiers in physiology · 2020Review
- Inhibition of NLRP3 Inflammasome: A Prospective Target for the Treatment of Ischemic Stroke.Frontiers in cellular neuroscience · 2020Review
- Serum Amyloid A-Mediated Inflammasome Activation of Microglial Cells in Cerebral Ischemia.The Journal of neuroscience : the official journal of the Society for Neuroscience · 2019Article
- Inflammasome Signaling and Impaired Vascular Health in Psoriasis.Arteriosclerosis, thrombosis, and vascular biology · 2019Article
- Female Heart Health: Is GPER the Missing Link?Frontiers in endocrinology · 2019Review
- NLRP1 promotes TGF-β1-induced myofibroblast differentiation in neonatal rat cardiac fibroblasts.Journal of molecular histology · 2018Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
1 author.
Funding
Abstract
NOD-like receptors (NLRs) constitute a recently identified family of macromolecules that participate in regulation of innate immune responses. To date, 23 members of the NLR family are identified in humans. Diverse NLRs are stimulated by a broad range of pathogen- or danger-associated molecular patterns, and collectively function as intracellular pattern recognition receptors (PRRs). The most studied inflammasomes are NLRP1 and NLRP3 that process inactive pro-caspase-1 to its active form, allowing the cleavage and subsequent activation of pro-IL-1β and pro-IL-18, and initiation of inflammatory responses. Three models, based upon extracellular ATP/K(+) flux, lysosomal release of cathepsin, and reactive oxygen species, have been proposed to be involved in signaling activation of NLRs and downstream events. In this review, I discuss the current state of knowledge related to the roles of NLRs and inflammasomes in the development of cardiovascular diseases.
Indexed as
Identifiers
22254202PMC3253520W4899446What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.